<DOC>
	<DOCNO>NCT00087035</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel , work different way stop tumor cell divide stop grow die . Erlotinib may stop growth tumor cell block enzymes necessary growth . Combining docetaxel erlotinib may kill tumor cell . PURPOSE : This phase II trial study well give docetaxel together erlotinib work treat old patient progressive prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>Docetaxel Erlotinib Treating Older Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate response duration old patient progressive hormone refractory prostate cancer treat docetaxel erlotinib . Secondary - Determine safety regimen patient . - Evaluate quality life patient treat regimen . OUTLINE : This multicenter study . - Initial combination therapy : Patients receive docetaxel IV 1 hour day 1 oral erlotinib daily day 1-21 . Treatment repeat every 21 day 9 course absence disease progression unacceptable toxicity . Patients respond disease receive 3 additional course beyond maximal response . - Extension phase : After 9 course initial combination therapy , patient achieve complete response , partial response , stable disease receive 8 course erlotinib alone ( total 17 course study treatment ) . Quality life assess baseline , day 1 course , end study treatment . For patient extension phase , quality life also assess day 1 course 10 , 12 , 14 , 16 . Patients follow every 3 month . PROJECTED ACCRUAL : A total 22 patient accrue study within 24 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Inclusion Criteria Histologically confirm adenocarcinoma prostate . Disease progression follow primary secondary hormonal therapy . All patient must maintain GnRH analog study . Serum PSA must &gt; 20 ng/mL patient without bidimensionally measurable disease bone disease . Age &gt; 65 year . Karnofsky performance status &gt; 70 % . Life Expectancy &gt; 12 week . Peripheral neuropathy , present must &lt; grade 1 NCI criterion . Radionuclide bone scan chest /abdominal/pelvic CT scan must obtain patient within 4 week prior cycle 1/day 1 . Sexually active men must willing consent use effective contraception treatment 6 month follow treatment . No concomitant use prostata saw palmetto . Testosterone must castrate level ( &lt; 50 ng/ml ) . WBC &gt; 2.8 x 109/L Granulocytes &gt; 1.5 x 109/L Platelets &gt; 100 x 109/L Hemoglobin &gt; 8.0 g/dL Serum creatinine &lt; 2.1 Total bilirubin &lt; ULN Alkaline Phosphatase &lt; 2.5 ULN AND ALT/AST &lt; 2.0 ULN OR Alkaline Phosphatase 2.63.9 ULN , AND ALT/AST &lt; 1.5 ULN OR Patients know bone involvement may include alkaline phosphatase &gt; 4.0 ULN , IF ALT AST total bilirubin within normal range bone involvement think account elevated alkaline phosphatase . PT , INR within physiologic limit , i.e . INR 0.7 1.5 . If patient receive anticoagulation therapy INR within range 2.0 3.5 . Exclusion Criteria Any major surgery radiotherapy , within 4 week prior cycle 1/day 1 ( within 12 week previous treatment strontium89 , rhenium , sumarium ) . Hormonal therapy , exception androgen deprivation therapy stable regimen prednisone dexamethasone , ( change within 2 week prior cycle1/day 1 ) . Prior prostate hormonal treatment must discontinue least four week ( 6 week Casodex ) prior cycle1/day 1 . Cardiovascular : Uncontrolled hypertension ( rest blood pressure &gt; 160/100 mm/Hg ) ; clinical episode congestive heart failure , angina pectoris , myocardial infarction within last year . Any active infection ( require IV antibiotic ) . Any prior chemotherapy . Not reliable adequate followup . History severe hypersensitivity reaction drug formulate polysorbate 80 . Brain metastasis ( clinical sign ) brain involvement leptomeningeal disease . Patients history another malignancy last 5 year prostate cancer , nonmelanomatous skin cancer situ bladder cancer ( Stage T1a ) . Concurrent commercial investigational antineoplastic therapy .</criteria>
	<gender>Male</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>